Enhanced immunoreactivity of ras oncogene p21 protein in urinary bladder epithelium of rats treated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide

T. Masui, J. M. Ward, Samuel Monroe Cohen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Normal urothelium and various lesions of the rat urinary bladder induced by the dietary administration of 0.2% N-[4-(5-nitro-2-furyl)-2-thiazoyl]formamide (FANFT) (up to 77 weeks) or by the combination of 0.2% FANFT and the subsequent administration of 5% sodium saccharin or 2% dl-tryptophan (up to 104 weeks) were evaluated for immunoreactivity with monoclonal antibody to ras p21 by avidin-biotin immunohistochemistry. Seventyone to 100% of transitional cell carcinomas showed strong reactivity to the antibody to ras p21 depending on treatment with long-term administration of FANFT or by 6 weeks administration of FANFT followed by sodium saccharin or dl-tryptophan. Focal reactivity to the ras p21 antibody was frequently observed in the hyperplastic (57-96%) or normal appearing urinary bladder epithelium (50-100%) in rats treated with FANFT (FANFT alone or in combination with sodium saccharin or tryptophan) but not in hyperplasia or normal epithelium in rats given sodium saccharin or tryptophan alone, without pretreatment with FANFT or in untreated controls. The present results show that there is a close association of enhanced immunoreactivity with ras p21 antibody in the urinary bladder epithelium to FANFT treatment, and that ras p21 is expressed in normal, hyperplastic and neoplastic lesions of the bladder of rats treated with FANFT. These results suggest that enhanced immunoreactivity with ras p21 is observed as a consequence of the treatment with FANFT but it alone does not reflect the progression from benign to malignant lesions.

Original languageEnglish (US)
Pages (from-to)95-102
Number of pages8
JournalCancer Letters
Volume59
Issue number2
DOIs
StatePublished - Aug 1991

Fingerprint

FANFT
Oncogene Protein p21(ras)
Proto-Oncogene Proteins p21(ras)
Urinary Bladder
Epithelium
Saccharin
Tryptophan
Antibodies
formamide
Urothelium
Avidin
Transitional Cell Carcinoma
Biotin
Hyperplasia

Keywords

  • N-[4-(5-nitro-2-furyl)-2-thiazoyl]formamide
  • p21
  • ras oncogene
  • rat
  • urinary bladder

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{d579fd1111c64f1e962dabbdf5f01583,
title = "Enhanced immunoreactivity of ras oncogene p21 protein in urinary bladder epithelium of rats treated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide",
abstract = "Normal urothelium and various lesions of the rat urinary bladder induced by the dietary administration of 0.2{\%} N-[4-(5-nitro-2-furyl)-2-thiazoyl]formamide (FANFT) (up to 77 weeks) or by the combination of 0.2{\%} FANFT and the subsequent administration of 5{\%} sodium saccharin or 2{\%} dl-tryptophan (up to 104 weeks) were evaluated for immunoreactivity with monoclonal antibody to ras p21 by avidin-biotin immunohistochemistry. Seventyone to 100{\%} of transitional cell carcinomas showed strong reactivity to the antibody to ras p21 depending on treatment with long-term administration of FANFT or by 6 weeks administration of FANFT followed by sodium saccharin or dl-tryptophan. Focal reactivity to the ras p21 antibody was frequently observed in the hyperplastic (57-96{\%}) or normal appearing urinary bladder epithelium (50-100{\%}) in rats treated with FANFT (FANFT alone or in combination with sodium saccharin or tryptophan) but not in hyperplasia or normal epithelium in rats given sodium saccharin or tryptophan alone, without pretreatment with FANFT or in untreated controls. The present results show that there is a close association of enhanced immunoreactivity with ras p21 antibody in the urinary bladder epithelium to FANFT treatment, and that ras p21 is expressed in normal, hyperplastic and neoplastic lesions of the bladder of rats treated with FANFT. These results suggest that enhanced immunoreactivity with ras p21 is observed as a consequence of the treatment with FANFT but it alone does not reflect the progression from benign to malignant lesions.",
keywords = "N-[4-(5-nitro-2-furyl)-2-thiazoyl]formamide, p21, ras oncogene, rat, urinary bladder",
author = "T. Masui and Ward, {J. M.} and Cohen, {Samuel Monroe}",
year = "1991",
month = "8",
doi = "10.1016/0304-3835(91)90172-E",
language = "English (US)",
volume = "59",
pages = "95--102",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Enhanced immunoreactivity of ras oncogene p21 protein in urinary bladder epithelium of rats treated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide

AU - Masui, T.

AU - Ward, J. M.

AU - Cohen, Samuel Monroe

PY - 1991/8

Y1 - 1991/8

N2 - Normal urothelium and various lesions of the rat urinary bladder induced by the dietary administration of 0.2% N-[4-(5-nitro-2-furyl)-2-thiazoyl]formamide (FANFT) (up to 77 weeks) or by the combination of 0.2% FANFT and the subsequent administration of 5% sodium saccharin or 2% dl-tryptophan (up to 104 weeks) were evaluated for immunoreactivity with monoclonal antibody to ras p21 by avidin-biotin immunohistochemistry. Seventyone to 100% of transitional cell carcinomas showed strong reactivity to the antibody to ras p21 depending on treatment with long-term administration of FANFT or by 6 weeks administration of FANFT followed by sodium saccharin or dl-tryptophan. Focal reactivity to the ras p21 antibody was frequently observed in the hyperplastic (57-96%) or normal appearing urinary bladder epithelium (50-100%) in rats treated with FANFT (FANFT alone or in combination with sodium saccharin or tryptophan) but not in hyperplasia or normal epithelium in rats given sodium saccharin or tryptophan alone, without pretreatment with FANFT or in untreated controls. The present results show that there is a close association of enhanced immunoreactivity with ras p21 antibody in the urinary bladder epithelium to FANFT treatment, and that ras p21 is expressed in normal, hyperplastic and neoplastic lesions of the bladder of rats treated with FANFT. These results suggest that enhanced immunoreactivity with ras p21 is observed as a consequence of the treatment with FANFT but it alone does not reflect the progression from benign to malignant lesions.

AB - Normal urothelium and various lesions of the rat urinary bladder induced by the dietary administration of 0.2% N-[4-(5-nitro-2-furyl)-2-thiazoyl]formamide (FANFT) (up to 77 weeks) or by the combination of 0.2% FANFT and the subsequent administration of 5% sodium saccharin or 2% dl-tryptophan (up to 104 weeks) were evaluated for immunoreactivity with monoclonal antibody to ras p21 by avidin-biotin immunohistochemistry. Seventyone to 100% of transitional cell carcinomas showed strong reactivity to the antibody to ras p21 depending on treatment with long-term administration of FANFT or by 6 weeks administration of FANFT followed by sodium saccharin or dl-tryptophan. Focal reactivity to the ras p21 antibody was frequently observed in the hyperplastic (57-96%) or normal appearing urinary bladder epithelium (50-100%) in rats treated with FANFT (FANFT alone or in combination with sodium saccharin or tryptophan) but not in hyperplasia or normal epithelium in rats given sodium saccharin or tryptophan alone, without pretreatment with FANFT or in untreated controls. The present results show that there is a close association of enhanced immunoreactivity with ras p21 antibody in the urinary bladder epithelium to FANFT treatment, and that ras p21 is expressed in normal, hyperplastic and neoplastic lesions of the bladder of rats treated with FANFT. These results suggest that enhanced immunoreactivity with ras p21 is observed as a consequence of the treatment with FANFT but it alone does not reflect the progression from benign to malignant lesions.

KW - N-[4-(5-nitro-2-furyl)-2-thiazoyl]formamide

KW - p21

KW - ras oncogene

KW - rat

KW - urinary bladder

UR - http://www.scopus.com/inward/record.url?scp=0025808119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025808119&partnerID=8YFLogxK

U2 - 10.1016/0304-3835(91)90172-E

DO - 10.1016/0304-3835(91)90172-E

M3 - Article

C2 - 1884376

AN - SCOPUS:0025808119

VL - 59

SP - 95

EP - 102

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -